Pharma models changing as patents expire and product lines get smaller
Anyone watching stock markets recently will have noticed that despite overall gains, the pharmaceutical sector has not been performing. Not surprisingly, it is a combination of drugs coming off patent and a lack of a products in the pipeline that…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.